TickerFacts.

Company research / NRSN

NeuroSense Therapeutics Ltd. (NRSN)

Also trades as NRSNW. Every security a company lists rests on one set of financial statements, so these figures cover the whole company.

Build a valuation ↗↓ Download CSV

CIK 0001875091 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Fiscal year ends Dec 31

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 6-K (current report) · 2026-10-02

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

Period ended2025-12-312024-12-312023-12-312022-12-31
R&D Expense$6.23M$5.70M$7.27M$5.59M
Operating Income-$11.09M-$9.90M-$12.05M-$10.55M
Net Income-$11.12M-$10.21M-$10.11M-$10.49M
EPS (Diluted)-$0.44-$0.54-$0.74-$0.91
Total Assets$1.03M$4.58M$3.19Mn/a
Total Liabilities$2.59M$1.99M$4.94Mn/a
Shareholders' Equity-$1.56M$2.58M-$1.76M$5.84M
Cash & Equivalents$166.0K$3.38M$2.64Mn/a
Operating Cash Flow-$7.67M-$10.13M-$8.35M-$7.62M
Capital Expenditures$8.0K$3.0K$29.0K$70.0K
Free Cash Flow-$7.68M-$10.14M-$8.38M-$7.69M
Shares Outstanding32.56M23.23M15.38Mn/a
Weighted Average Diluted Shares25.48M18.60M13.64M11.50M
EPS (Basic)-$0.44-$0.54-$0.74-$0.91

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView